

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hua Han Health Industry Holdings Limited
華瀚健康產業控股有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 587)

**DELAY IN PUBLICATION OF ANNUAL RESULTS FOR THE
YEAR ENDED 30 JUNE 2017;
AND
DELAY IN DESPATCH OF THE 2016/2017 ANNUAL REPORT**

This announcement is made by Hua Han Health Industry Holdings Limited (the “**Company**“, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated 12 December 2016 in relation to the conditions imposed by the Stock Exchange on the Company in respect of the resumption of trading in the shares of the Company on the Stock Exchange (the “**Resumption Conditions Announcement**”); and (ii) the announcement of the Company dated 26 September 2017 (the “**September Update Announcement**”) and the announcements referred to therein. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the September Update Announcement.

**DELAY IN PUBLICATION OF ANNUAL RESULTS FOR THE YEAR ENDED 30
JUNE 2017 AND DELAY IN DESPATCH OF THE 2016/2017 ANNUAL REPORT**

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the annual results of the Group for the year ended 30 June 2017 (the “**2016/2017 Annual Results**”) on a date not later than three months after the end of the financial year, i.e. 30 September 2017.

Pursuant to Rule 13.46(2) of the Listing Rules, the Company is required to send its annual report including the consolidated financial statements of the Group for the year ended 30 June 2017 and a copy of the auditors’ report thereon (the “**2016/2017 Annual Report**”) to its shareholders not less than 21 days before the date of the Company’s annual general meeting and in any event not more than four months after the end of the financial year to which they relate, i.e. 31 October 2017.

As set out in the September Update Announcement, the process of providing all necessary documents and information to Grant Thornton and ZHONGHUI is still ongoing. In view of the above, the publication of the 2016/2017 Annual Results is delayed and such delay constitutes non-compliance with Rule 13.49(1) of the Listing Rules. The despatch of the 2016/2017 Annual Report is also expected to be delayed and the Board acknowledges that such delay will constitute non-compliance with Rule 13.46(2) of the Listing Rules.

EXPECTED TIMELINE FOR PUBLICATION OF OUTSTANDING FINANCIAL RESULTS

Set out below is the expected timeline in respect of the publication of the 2015/2016 Annual Results, the interim results of the Company for the six months ended 31 December 2016 (the “**2016/2017 Interim Results**”) and the 2016/2017 Annual Results (collectively, the “**Outstanding Financial Results**”):

Expected timeline:

Publication of the 2015/2016 Annual Results, and address audit qualifications (if any)	In the fourth quarter of the calendar year of 2017, subject to the findings of the Investigation
Publication of the 2016/2017 Interim Results	In the first quarter of the calendar year of 2018, subject to the findings of the Investigation
Publication of the 2016/2017 Annual Results, and address audit qualifications (if any)	In the first quarter of the calendar year of 2018, subject to the findings of the Investigation
Publication of the annual reports of the Company for each of the years ended 30 June 2016 and 2017, and the interim report of the Company for the six months ended 31 December 2016	In the first quarter of the calendar year of 2018, subject to the findings of the Investigation

Note: The expected timeline above is indicative only and may be further revised depending on the circumstances.

The Company has been actively undertaking the necessary actions to publish the Outstanding Financial Results in accordance with the above timeline. The Company is working closely with ZHONGHUI to ensure that completion of their audit work will adhere to the above timeline.

The Company will publish further announcement(s) to update the shareholders of the Company and the investing public as and when appropriate.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Company's shares (stock code: 00587) and debt securities (stock code: 05676) has been suspended on the Stock Exchange with effect from 9:00 a.m. on Tuesday, 27 September 2016 and will remain suspended until further notice.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board of
Hua Han Health Industry Holdings Limited
Zhang Peter Y.
Chairman

Hong Kong, 3 October 2017

As at the date of this announcement, the Board comprises Mr. Zhang Peter Y., Mr. Deng Jie, Mr. Zhou Chong Ke, Mr. Bian Shu Guang and Ms. Niu Yi as executive Directors, Mr. Tarn Sien Hao as non-executive Director, and Professor Lin Shu Guang, Professor Zhou Xin and Mr. Chan Chun Kit as independent non-executive Directors.